Channel Expansion Current partnerships with Tebubio and prior collaboration with Cell Systems demonstrate a proven channel path; prioritize expanding distributor networks across Europe and North America, targeting pharma, CROs, and academic labs that need organ-specific 3D culture models.

Physiological Readouts 4Dcell’s 3D culture platform controls the cell microenvironment to deliver more physiologically relevant readouts, enabling better predictive studies in oncology, immunology, and organ-level biology for drug discovery and toxicology.

Broad Applications A diverse model portfolio spanning cancer, immune studies, heart and gut organs, neuronal networks, stem cells, and genetic disorders creates multiple high-potential BD opportunities; tailor pitches to therapeutic areas with the strongest unmet needs.

Agile SMB Advantage As a small team, leverage speed and flexibility by offering pilot collaborations with CROs or distributors, scalable pricing, and rapid deployment to win early adopters in EU markets and drive word-of-mouth.

Competitive Position In a crowded market with larger players, position 4Dcell as a specialized provider delivering close-to-native microenvironments and easy workflow integration, using distributor-led case studies such as Tebubio and Cell Systems to establish credibility.